Granulomatosis with polyangiitis - Pipeline Insight, 2024

This “Granulomatosis with polyangiitis - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Granulomatosis with polyangiitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Granulomatosis with polyangiitis Understanding

Granulomatosis with polyangiitis: Overview

Granulomatosis with polyangiitis formerly known as Wegener's granulomatosis is an uncommon disorder that causes inflammation of the blood vessels in your nose, sinuses, throat, lungs and kidneys. It is classified as an autoimmune disorder. It is the result of inflammation within the tissues called granulomatous inflammation and blood vessel inflammation (vasculitis), which can damage organ systems. The area’s most commonly affected by GPA include the sinuses, lungs, and kidneys, but any site can be affected. Granulomatosis with Polyangiitis is nearly equally distributed between the sexes, with a slight male predominance. Granulomatosis with Polyangiitis typically occurs in middle age, but is found in people of all ages.

Symptoms

• Loss of appetite
• Weight loss
• Fever
• Fatigue
• Nasal or facial pain
• Nose bleeds or unusual nasal discharge, caused by inflammation of the nose or sinuses
• Chest discomfort with or without shortness of breath
• Joint pain
• Rashes or skin sores

Diagnosis
A diagnosis of granulomatosis with polyangiitis is made based upon a thorough clinical evaluation including routine laboratory tests, a detailed patient history, identification of relevant symptoms, and a variety of specialized tests. One way in the diagnosis of Granulomatosis with Polyangiitis is by biopsying an involved organ and finding the pathologic features of this disease under the microscope. Chest X-rays, CT or MRI can help determine which blood vessels and organs are affected.Blood tests can check for: Signs of inflammation, Anti-neutrophil cytoplasmic antibodies and anemia.

Treatment
Treatment generally involves taking prescription drugs long term to prevent relapse.With early diagnosis and appropriate treatment, it becomes easy to recover from granulomatosis with polyangiitis within a few months. Corticosteroids such as prednisone help suppress the immune system and reduce inflammation of the blood vessels. Rituximab (Rituxan) is another option for treating granulomatosis with polyangiitis. In cases of very serious granulomatosis with polyangiitis, plasmapheresis can help the kidneys recover.

Granulomatosis with polyangiitis Emerging Drugs Chapters

This segment of the Granulomatosis with polyangiitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Granulomatosis with polyangiitis Emerging Drugs

Abatacept: University of South FloridaAbatacept inhibits T cell activation, selectively blocking specific binding of the CD80/CD86 receptor in APC to CD28 on T cells. The pharmacological strategy looks to inhibit the accelerated immune/inflammatory response, characteristic of the disease, and restore normal homeostasis in the immune system. It is Currently in phase III stage of development in collaboration with The Cleveland Clinic,Bristol-Myers Squibb,University of Pennsylvania,National Institutes of Health (NIH),National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

• IFX-1 (Vilobilemab):InflaRx GmbH

InflaRx GmbH in collaboration with Iqvia Pty Ltd has resulted in the development of IFX-1 i a monoclonal antibody specifically binding to the soluble human complement split product C5a and the resulting nearly complete blockade of C5a-induced biological effects. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in preclinical studies. IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development and has, to date, successfully completed three clinical phase II studies.

Granulomatosis with polyangiitis: Therapeutic Assessment

This segment of the report provides insights about the different Granulomatosis with polyangiitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Granulomatosis with polyangiitis

There are approx. 10+ key companies which are developing the therapies for Granulomatosis with polyangiitis. The companies which have their Granulomatosis with polyangiitis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, InflaRx GmbH and others.

Phases

This report covers around 10+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Granulomatosis with polyangiitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Granulomatosis with polyangiitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Granulomatosis with polyangiitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Granulomatosis with polyangiitis drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Granulomatosis with polyangiitis R&D. The therapies under development are focused on novel approaches to treat/improve Granulomatosis with polyangiitis.

Granulomatosis with polyangiitis Report Insights

• Granulomatosis with polyangiitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Granulomatosis with polyangiitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Granulomatosis with polyangiitis drugs?
• How many Granulomatosis with polyangiitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Granulomatosis with polyangiitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Granulomatosis with polyangiitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Granulomatosis with polyangiitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• InflaRx GmbH
• Bristol-Myers Squibb
• Hoffmann-La Roche
• Iqvia Pty Ltd

Key Products

• Abatacept
• IFX-1

This product will be delivered within 2 business days.